Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTR²: Tafasitamab, Lenalidomide, Rituximab, Methotrexate in PCNSL
NCT05583071Phase 2Recruiting
- Sponsor
- University of Cologne
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in primary central nervous system lymphoma (PCNSL), sponsored by University of Cologne. Started Aug 2024; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT05583071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583071.